BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents 1 – 5 . Here we show that se...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) Vol. 596; no. 7871; pp. 273 - 275
Main Authors: Liu, Jianying, Liu, Yang, Xia, Hongjie, Zou, Jing, Weaver, Scott C., Swanson, Kena A., Cai, Hui, Cutler, Mark, Cooper, David, Muik, Alexander, Jansen, Kathrin U., Sahin, Ugur, Xie, Xuping, Dormitzer, Philip R., Shi, Pei-Yong
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 12.08.2021
Nature Publishing Group
Subjects:
13
38/23
38/77
38/90
631/326/590/2293
631/326/596/4130
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Binding sites
BNT162 Vaccine
Causes of
Chemical compounds
Chlorocebus aethiops
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 vaccines
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Disease transmission
Glycoproteins
Health aspects
Humanities and Social Sciences
Humans
Immunization
Medical research
Medicine, Experimental
mRNA Vaccines
multidisciplinary
Mutation
Neutralization
Neutralization Tests
Pandemics
Pathogenicity
Pathogens
Pharmacology
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Science
Science (multidisciplinary)
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Vaccines
Vaccines, Synthetic - genetics
Vero Cells
Viral diseases
Viruses
United States
United Kingdom > UK
Nigeria
United States > US
India
ISSN:0028-0836, 1476-4687, 1476-4687
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents 1 – 5 . Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses—particularly the B.1.617.1 variant—seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. Samples of serum from individuals immunized with the BNT162b2 vaccine show neutralization activity against engineered SARS-CoV-2s bearing the spike mutations from B.1.617 and other variants.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/s41586-021-03693-y